Aclaris Therapeutics, Inc. (LON: 0H8T)
London
· Delayed Price · Currency is GBP · Price in USD
2.510
+0.011 (0.44%)
Jan 22, 2025, 6:28 PM BST
Aclaris Therapeutics Revenue
Aclaris Therapeutics had revenue of $4.35M USD in the quarter ending September 30, 2024, a decrease of -53.18%. This brings the company's revenue in the last twelve months to $27.08M, up 26.35% year-over-year. In the year 2023, Aclaris Therapeutics had annual revenue of $31.25M with 5.03% growth.
Revenue (ttm)
$27.08M
Revenue Growth
+26.35%
P/S Ratio
n/a
Revenue / Employee
$304.26K
Employees
89
Market Cap
225.86M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 31.25M | 1.50M | 5.03% |
Dec 31, 2022 | 29.75M | 22.99M | 340.05% |
Dec 31, 2021 | 6.76M | 279.00K | 4.30% |
Dec 31, 2020 | 6.48M | 2.26M | 53.35% |
Dec 31, 2019 | 4.23M | -1.92M | -31.28% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Aclaris Therapeutics News
- 16 days ago - Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy - Benzinga
- 4 weeks ago - Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy - Benzinga
- 7 weeks ago - Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 2 months ago - Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments - Benzinga
- 2 months ago - Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets - PRNewsWire
- 2 months ago - Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline - GlobeNewsWire